$CDXS (Codexis Inc) 🚀 After-Hours 📈
Codexis Takes a Giant Leap Forward in Gene-Editing Technology!!!
Codexis, today announced a groundbreaking breakthrough with its proprietary Enzyme-Catalyzed Oligonucleotide (ECO) Synthesis technology. The company has successfully demonstrated gram-scale synthesis of oligonucleotides, the building blocks of RNA therapeutics, under process-like conditions. This monumental achievement marks a pivotal step towards commercializing RNAi therapies and revolutionizing the field of gene editing.
✍️ 2-3 months ago, I have written about them but good to know that conventional RNA synthesis methods often involve complex and time-consuming processes, hindering the development of effective RNAi therapeutics. Codexis' ECO Synthesis technology, however, offers a transformative solution. By harnessing the power of enzymes, ECO Synthesis streamlines the synthesis process, enabling the production of high-quality oligonucleotides in a more efficient and cost-effective manner.
🚀 The successful demonstration of gram-scale synthesis with ECO Synthesis is a game-changer for the gene-editing industry. It paves the way for the large-scale production of RNAi therapeutics, opening up a vast array of therapeutic possibilities. From treating rare genetic disorders to developing cancer-fighting drugs, ECO Synthesis has the potential to transform the lives of countless individuals.
Codexis' groundbreaking achievement has already garnered significant attention from industry leaders and investors. The company's stock price has surged after hours in anticipation of the transformative impact of ECO Synthesis on the gene-editing landscape.
Final word:
As Codexis continues to advance its ECO Synthesis technology, the future of gene editing looks brighter than ever. The company is poised to become a key player in this rapidly evolving field, with the potential to revolutionize the way we treat diseases and improve human health.
BR/ A.H
$CDXS$NSDQ100$PFE (Pfizer)$MRNA (Moderna Inc)$JNJ (Johnson & Johnson)... Show More
